Showing results (641-650 of 1,011) with videos related to
Sort By:
Pageof 102
Public Health Reviews|October 10, 2022
Nation-Wide Routinely Collected Health Datasets in China: A Scoping ReviewYishu Liu, Shaoming Xiao, Xuejun Yin, et al.BMC Public Health|February 6, 2014
Cost-effectiveness of reducing salt intake in the Pacific Islands: protocol for a before and after intervention studyJacqui Webster, Wendy Snowdon, Marj Moodie, et al.The Lancet. Diabetes & Endocrinology|June 26, 2018
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trialsVlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, et al.Journal of the American Heart Association|December 2, 2021
Association Between Circulating GDF-15 and Cardio-Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS TrialTaha Sen, Jingwei Li, Brendon L Neuen, et al.Clinical Trials (London, England)|February 20, 2008
Do we need to adjudicate major clinical events?Christopher B Granger, Victor Vogel, Steve R Cummings, et al.Food Research International (Ottawa, Ont.)|May 31, 2021
The adaptation, validation, and application of a methodology for estimating the added sugar content of packaged food products when total and added sugar labels are not mandatoryTailane Scapin, Jimmy Chun Yu Louie, Simone Pettigrew, et al.Plos One|March 27, 2019
SMARThealth India: A stepped-wedge, cluster randomised controlled trial of a community health worker managed mobile health intervention for people assessed at high cardiovascular disease risk in rural IndiaDavid Peiris, Devarsetty Praveen, Kishor Mogulluru, et al.JAMA Cardiology|February 5, 2025
Salt Substitution and Recurrent Stroke and Death: A Randomized Clinical TrialXiong Ding, Xinyi Zhang, Liping Huang, et al.Diabetes Care|June 20, 2022
Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS)Ele Ferrannini, Simona Baldi, Tiziana Scozzaro, et al.Circulation|November 15, 2017
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)Kenneth W Mahaffey, Bruce Neal, Vlado Perkovic, et al.Pageof 102